Wilson Sonsini's 2024 Technology and Life Sciences IPO Report provides in-depth analysis on 33 initial public offerings (IPOs) completed by U.S.-based technology and life sciences companies in 2024 with deal values exceeding $75 million.

Highlights of our analysis include:

• Despite a lower overall IPO activity compared to the pandemic-era boom, 2024 witnessed a significant increase in deal volume, indicating a growing traction in the IPO market as macroeconomic conditions stabilized.
• Technology companies accounted for eight IPOs with deal values over $75 million, with software the leading sub-sector. On the other hand, 25 life sciences companies priced IPOs above the threshold, dominated by therapeutics companies. While life sciences IPOs had a higher number, technology IPOs generated larger deal values, with several exceeding $500 million.

The report also provides valuable insights for companies considering an IPO, including:

• Key Considerations Checklist for Late-Stage Private Companies
• Breakdown of Technology vs. Life Sciences 2024 IPO Activity
• Comparison of Offer Price to Initial Price Range and to First Day Close
• Analysis of Deal Size Distribution and Closing Distribution by Quarter
• Review of Defensive Measures to Prevent Hostile Takeovers

Click here to read the report.